Organization
Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France
1 abstract
Abstract
Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).Org: Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Vrije Universiteit Amsterdam, Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Levine Cancer Institute/Atrium Health, Charlotte, NC,